Identifying Targets of Maladaptive Metabolic Responses in Heart Failure

NCT03032627•AdventHealth Translational Research Institute

Summary

The purpose of the research is to help researchers understand changes in metabolism in patients that develop heart failure.

Eligibility

Age

19 - 89 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Subjects are capable of giving informed consent.
•2. Age 19-89
•3. Diagnosis of chronic heart failure
•4. Any patients scheduled for at least one of the following procedures:
•1. LVAD implantation or as recipient for cardiac transplantation.
•2. LVAD placement both as bridge to transplant and as destination therapy.
•3. LVAD explantation
•4. Valve replacement or repair
•5. Catheterization and myocardial biopsy for idiopathic cardiomyopathy
•6. Coronary artery bypass graft (CABG)
+2 more criteria

Exclusion Criteria

•1. Life expectancy less than 2 weeks
•2. Diagnosed with following co-morbidities: cancer, chronic kidney disease (GFR≤30 or serum creatinine \>2.1), active infection or treatment with antibiotics or persistent infectious disease (hepatitis, HIV, etc), cirrhosis, active substance abuse and/or alcohol dependence (≥ 14 alcoholic beverages per week).
•1. Pathological remodeling and extensive infarction with limited non-pathological regions of myocardium.
•2. Abnormal or impaired cardiac function from medical records, which are self determinants for rejection as a donor organ.

Locations (1)

Translational Research Institute for Metabolism and Diabetes

Orlando, Florida, United States

Key Dates

Start Date

March 20, 2017

Primary Completion Date

June 28, 2019

Completion Date

December 1, 2025

Last Updated

March 13, 2025

Enrollment

ACTUAL participants

Conditions

Heart Failure

Interventions

Collection of discarded heart tissue

PROCEDURE

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

NCT07484009

Acute Heart Failure (AHF)Heart Failure (for Example, Fluid Overload)+1 more

View study

RECRUITING

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

NCT07191730

CardiotoxicityHeart Failure+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 13, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Identifying Targets of Maladaptive Metabolic Responses in Heart Failure

Inclusion Criteria

Exclusion Criteria

ReDS-guided Decongestion Strategy in Patients Hospitalized for Heart Failure

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies

Proof-of-concept of a Behavioral Intervention to Improve the Cardiovascular Health of People Living With HIV

Hemodynamic Monitoring to Prevent Adverse Events foLlowing cardiOgenic Shock Trial

Autologous Induced Pluripotent Stem Cells of Cardiac Lineage for Congenital Heart Disease

Assessment of Physical Activity and Cardiovascular Outcomes in Patients With Chronic Heart Failure